Decision-grade intelligence needs traceable sources. This page explains how the LAI dataset is scoped, classified and sourced.
The scope is a deliberate, documented decision, revisited as the field evolves. An asset is in scope when its long duration is engineered: obtained from an identifiable delivery or half-life-extension technology, by an injectable route, and lasting far longer than the drug would on its own. Deliberately out of scope: vaccines, cell and gene therapies, surgically-placed or non-resorbable implants, and antibodies whose long half-life is natural rather than engineered.
In an LAI, duration of action comes from the technology: a drug delivery system that controls release, or a half-life extension that modifies the molecule. Assets are classified on independent axes that combine: an asset can be a physical depot, of a given matrix, on a given route.
The raw material is public: regulatory bodies such as the FDA and EMA, clinical registries, the scientific literature, corporate disclosures. Sources are monitored continuously and the dataset is updated as the field moves. The ontology, the delivery-technology taxonomy and the curation decisions that consolidate each entity into a single record are proprietary.
Where an FDA or EMA label exists, its facts carry a link to the official source: DailyMed for the FDA, the EMA register.
Delivery technology, release families, molecular properties, targets and other attributes are sourced from company disclosures, ClinicalTrials.gov, PubMed and ChEMBL, then curated and standardized in Vectora’s ontology for consistent comparison across the scope.
The ontology, the delivery-technology taxonomy, and the scope are defined and maintained by a specialist in pharmaceutical competitive intelligence. These editorial decisions (which assets qualify, how each technology is classified) are specific to the LAI field.
Vectora is available to teams working in Long-Acting Injectables.
Request access